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Abstract
The current global spread of multi-resistant Gram-negatives, particularly extended spectrum β-lactamases
expressing bacteria, increases the likelihood of inappropriate empiric treatment of critically ill patients with
subsequently increased mortality. From a clinical perspective, fast detection of resistant pathogens would allow a
pre-emptive correction of an initially inappropriate treatment. Here we present diagnostic amplification-sequencing
approach as proof of principal based on the fast molecular detection and correct discrimination of CTX-M-β-
lactamases, the most frequent ESBL family. The workflow consists of the isolation of total mRNA and CTX-M-specific
reverse transcription (RT), amplification and pyrosequencing. Due to the high variability of the CTX-M-β-lactamase-
genes, degenerated primers for RT, qRT as well as for pyrosequencing, were used and the suitability and
discriminatory performance of two conserved positions within the CTX-M genes were analyzed, using one protocol
for all isolates and positions, respectively. Using this approach, no information regarding the expected CTX-M variant
is needed since all sequences are covered by these degenerated primers. The presented workflow can be conducted
within eight hours and has the potential to be expanded to other β-lactamase families.
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Introduction
The number of ESBLs of the CTX-M-type has increased
dramatically in the past ten years, and the majority of 3rd
generation cephalosporin resistant clinical isolates of
Escherichia coli and Klebsiella pneumoniae produce these
enzymes [1]. Besides CTX-M, clinical isolates often harbor
many other β-lactamases (e.g. TEM, SHV, OXA). The increase
of CTX-M-producers has led to an increasing use of
carbapenems resulting in the emergence of carbapenem
resistant Enterobacteriaceae.
The CTX-M enzymes belong to class A of the serine-β-
lactamases and were named in reference to their uncommon
preference to hydrolyze cefotaxime and cefepime more
effectively than ceftazidime [2]. However, in the past years,
CTX-M ESBLs, with highly increased hydrolyzing activity
against ceftazidime (e.g. CTX-M-15), have been frequently
observed in human and animal isolates as well as in
environmental samples [3,4,5]. Based on the phylogenetic
properties approximately 120 CTX-M variants are described so
far, that cluster into five main groups [6].
Nucleic acid testing (NAT) based detection of CTX-M β-
lactamases is fast but challenging, because to our knowledge
non of the commercially available NAT-based tests for bacterial
infections is able to detect all CTX-M variants [7]. They focus
instead on species determinants and the detection of some
individual frequent CTX-M variants. Such an approach is of
limited use because CTX-M evolution, i.e. the rise of novel
variants and composition of regional circulating CTX-M
variants, are subjects to a dynamic change and the
epidemiology exhibits large regional differences [8].
The spread of Gram-negative bacteria producing extended-
spectrum β-lactamases (ESBL) has become a rising problem
worldwide. Several clinical studies have shown that blood
stream infections with enterobacteria expressing ESBL are
associated with an increase in mortality rates [9,10]. This
increased mortality is not caused by an enhanced virulence of
the culprit pathogen, but by initial inappropriate treatment
resulting in clinical failure [11,12]. Empiric treatment suggested
by most sepsis guidelines (i.e. β-lactam with antipseudomonal
activity, in optional combination with an aminoglycoside or a
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fluoroquinolone) does not always cover ESBL producers
[13,14,15,16].
Since blood culture results are available only after 2 - 4 days
and a delay in antibiotic treatment by more than 1 hour is
already associated with an increase in mortality in critically ill
patients [17], guidelines recommend that empiric treatment
should be based on local resistance rates and individual patient
risk factors [18]. However, these “risk factors” (i.e. prior
antimicrobial treatment, hospitalization for > 4 days, etc.) are
poorly defined, and may result in inappropriate treatment for
the individual patient. Therefore an early detection of ESBL
expressing pathogens is crucial for individual patient outcome.
PCR-based determination of β-lactamases is facing the
following challenges: i) some types exhibit strong sequence
discrepancies, disabling primer-annealing within one type; ii)
different CTX-M variants exhibit different substrate spectra,
therefore discrimination to the type level is required; iii) the
presence of more than one CTX-M variant within the same
bacterium and iv) detection of the gene does not necessarily
mean expression of the enzyme [19,20].
These obstacles could be resolved by a strategy combining
reverse transcription of mRNA and subsequent amplification,
followed by fast sequencing of a specific mutation hot spot that
will allow discrimination of CTX-M-types on single nucleotide
level. However, some CTX-M-variants exhibit substitutions that
spread nearly over the entire sequence. Therefore, a
comprehensive identification of all relevant substitutions and
sequence homologies related to phenotypic resistance is
needed to allocate the appropriate regions for PCR and
pyrosequencing, and to develop PCR conditions that are
feasible for a transfer into clinical routine testing. Here we
present our efforts to identify adequate regions within the huge
and steadily increasing number of CTX-M variants that allow a
fast detection and accurate identification of individual CTX-M
variants.
Materials and Methods
Bacterial strains and antimicrobial susceptibility
testing
Bacterial strains used in this work were mainly clinical
isolates (n=16) of Enterobacteriaceae, with resistance to 3rd
generation cephalosporin’s and/or carbapenems (Table 1).
These strains were pre-characterised in the Robert-Koch-
Institute using PCR and sequencing of various β-lactamase
genes (blaTEM-type, blaSHV-type, blaCTX-M-type, blaOXA-type, blaNDM-type) as
described previously [21,22,23]. The three control strains
contained other β-lactamases than CTX-M, including one E.
coli strain CS01 bearing the TEM-2 β-lactamase, and that was
constructed by transformation of the pET15b plasmid into Ca2+-
competent JM109 cells, as described previously [24]. We also
analyzed the specificity of the method, by detection and
identification of CTX-M transcripts derived from strains bearing
up to 7 different β-lactamases, which encompass most
common variants.
Determination of antimicrobial susceptibilities to
carbapenems (ertapenem, imipenem, meropenem), and 12
further antibiotics (ampicillin, cefotaxime, ceftazidime, cefoxitin,
nalidixic acid, ciprofloxacin, gentamicin, amikacin,
streptomycin, chloramphenicol, tetracycline and trimethoprim/
sulfamethoxazole), were performed by Etest (bioMérieux,
Nuertingen, Germany) and microbroth dilution, respectively,
according to the CLSI criteria [25].
RNA isolation
All strains were grown in Mueller-Hinton (MH) medium (Roth)
supplied with 16 μg/ml cefotaxime (Fresenius Kabi) or 100
μg/ml ampicillin (Roth) at 37 °C for 5 hours. A culture volume of
3 ml was directly used for total RNA isolation.
Bacterial RNA was extracted using a TempusTM Blood RNA
Tube and TempusTM Spin RNA Isolation Kit according to the
manufacturer instructions (Life Technologies). DNase digestion
was carried out using AbsoluteRNA Wash Solution (Life
Technologies) on the column. After elution with RNase-free
water (Fermentas) RNA samples were stored at -80 °C. RNA
quality and quantity were analyzed using an Agilent
Bioanalyzer 2100 (Agilent Technologies). All reagents were
obtained from Agilent Technologies and measurements were
performed according to manufacture’s protocol. The RNA
samples were diluted in RNase-free water to a final
concentration of about 2 ng/µl, and denaturized at 72 °C for 3
min. Pico RNA Chip and the Prokaryote Total RNA Pico assay
were used to quantify total RNA and to determine the RIN
value, expressing the quality of the prepared RNA based on
16S and 23S rRNA. For the further analysis only RNA samples
were used that exhibited a RIN > 7.5.
Table 1. Bacterial strains used in this study.
Isolate's name Species Target CTX-M   Other β-lactamases
RKI 26/08 E. coli CTX-M-1  
RKI 443/08 E. coli CTX-M-14  
RKI 25/08 E. coli CTX-M-15  
RKI 427/08 E. coli CTX-M-27 TEM-1
RKI 29/04 E. coli CTX-M-3  
RKI 128/04 E. coli CTX-M-2  
CS 01 E. coli  TEM-2
RKI 2/10* E. coli CTX-M-15
TEM-1, OXA-1, OXA-2,
NDM-1
RKI 209/10* S. enterica CTX-M-8  
RKI K.p. 36 SHV K. pneumoniae  SHV-4
RKI 28/08 K. pneumoniae  OXA-10, SHV-5




RKI 346/12 K. pneumoniae CTX-M-15
TEM-1, SHV-1, OXA-1,
OXA-9, OXA-48
RKI VW823 E. cloacae CTX-M-25 SHV-11, TEM-1
RKI 428/08 E. cloacae CTX-M-9  
RKI 1/10* E. cloacae CTX-M-15 TEM-1, OXA-1, OXA-48
RKI 181/13 K. oxytoca  OXY
* Further characteristics of these isolates were described in other studies
[21,23,37,38]
doi: 10.1371/journal.pone.0080079.t001
Detection of CTX-M-Type ESBLs
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e80079
Reverse Transcription (RT)
Corresponding to specific resistance pattern we used
degenerated primers for reverse transcription, PCR and
pyrosequencing. The annealing-reactions were performed in 20
µl volume containing 10 ng of total RNA and 20 µM of
degenerated and 5'-biotinylated reverse primers revCTX-M314
(TCVGCAATSGGATTRTAGTTAAYMA) and revCTX-M739
(GCCARATVACCGCRATATCRTT) corresponding to positions
+314 to +339 and +739 to +761, respectively. Each reaction
mix was incubated for 6 min at 72 °C and cooled down to 37 °C
in a thermo-cycler. After addition of the RT-master-mix, the
samples were incubated at 37 °C for 60 min, followed by the
denaturation step at 94 °C for 10 min. RT-master-mix was
composed of 0.167 mM dNTPs each (Roth), 0.6 U/µl RNase
Inhibitor (Life Technologies), 1 x reaction buffer supplied by
manufacturer (Sensiscript RT Kit, Qiagen), 0.33 U/µl
Sensiscript (Sensiscript RT Kit, Qiagen), and 0.1 mg/ml BSA
(Life Technologies).
Real-Time PCR
Prior to the qRT, we used 10 ng total RNA prepared from
clinical ESBL isolates (Table 1) bearing members of the five
phylogenetic CTX-M groups, as well as 13 related serine-β-
lactamases of different classes (TEM-1, TEM-2, SHV-1,
SHV-4, SHV-5, SHV-28, OXA-1, OXA-2, OXA-9, OXA-10,
OXA-48, CMY, AmpC) and one metallo-β-lactamase (NDM-1),
to produce two cDNA transcripts by reverse transcription using
degenerated primers revCTX-M314 and revCTX-M739. The cDNA
transcripts were amplified by qRT using degenerated PCR-
primer sets forCTX-M67 / revCTX-M314 and forCTX-M314 / revCTX-M739. The
primers were designed based on conserved sequence regions
of all CTX-M variants (for details see Figure 1). The
quantitative real-time PCR (qRT) was performed in a Rotor-
GeneQ cycler (Qiagen), by directly applying 2 µl of the RT
reaction and the degenerated primer sets blaCTX-M67
(AGYGYRMCGCTKYATGCGCARR, corresponding to position
+67 to +89) and revCTX-M314 as well as forCTX-M314
(TKRTTAACTAYAATCCSATTGCBGA) corresponding to
position +314 to +339 and revCTX-M739. Both reverse primers
were initially used for reverse transcription. PCR reaction
mixture was composed of 1.8 mM MgCl2, 1 x PCR buffer (Life
technologies), 0.2 mM dNTPs (Roth), 0.6 µM of each primer
(Sigma Aldrich), 0.15x SybrGreen (Life Technologies), 0.08
U/µl Platinum Taq DNA Polymerase (Life Technologies), and
0.1 mg/ml BSA (Life Technologies). The PCR was run as
follows: pre-denaturation at 99 °C for 10 s and 95 °C for 50 s;
45 cycles composed of 95 °C for 20 s, 51 °C for 20 s and 72 °C
for 20 s. The melting temperatures of PCR-products were
determined by stepwise increasing (0.5 °C / 4 s) of the
temperature (from 75 °C to 99 °C). A linearized plasmidal CTX-
M-15 gene was used as a molecular copy standard.
Pyrosequencing
Pyrosequencing analysis was performed on the PyroMark
Q24 (Qiagen). A PCR reaction volume of 20 µl was added to
the pyrosequencing reaction mixture (PyroMark Gold Q24
reagent, Qiagen). The CTX-M sequence was analyzed using
the sequencing primer seqCTX-M211 (ATGTGCAGYACCAGTA) or
seqCTX-M705 (BGATAARACCGGCAG) annealing at positions
+211 to +226, or +705 to +720, respectively. All remaining
reagents were provided by the manufacturer (PyroMark Gold
Q24 reagents, Qiagen), and measurement was performed
according the manufactures protocol.
Sequence alignment
In total, 120 blaCTX-M gene sequences available online at the
National Center for Biotechnology Information (NCBI) could be
analyzed using DS Gene 1.5 software (Accelrys Ltd). The
nucleic acid sequences were aligned according to the multiple
alignment method ClustalW (open gap penalty 10, extended
gap penalty 5). For the phylogenetic calculations we used the
tree building method TreeDyn [26] (construction: PhyML).
Results and Discussion
Lineage of CTX-M types and unambiguous mutations’
positions
Referring to nucleic acid homologies, gene sequences of all
known CTX-M-variants (n=120) were extracted from the gene
bank (NCBI), aligned and displayed in a phylogenetic tree, that
revealed the expected relationships by dividing the CTX-M-
variants into the known 5 lineages [27] (for details see Figure
S1). In total, CTX-M group 9 contains 40 closely related
sequences, within which CTX-M-9, -14 and CTX-M-27 are the
main clinically relevant variants [28]. CTX-M group 1 involves
46 enzyme variants, including the widespread and clinically
relevant CTX-M-1, -3, -15 and CTX-M-32 [29]. CTX-M group 2
includes 19 sequences with CTX-M-2 representing the most
common β-lactamase [6]. Group 8 and group 25 contain only 3
and 9 enzyme variants of minor clinical importance. Detailed
reviews on clinically relevant CTX-Ms were published
elsewhere [29,30,31]. Two variants, CTX-M-74 and -75, are not
assigned to any group, but they seem to be closely related to
CTX-M group 2.
Based on the alignments, we found one sequence position
(+227 to +246, relative to ATG) appropriate for discrimination
between all phylogenetic groups of the CTX-M β-lactamases. A
second region (+720 to +747), corresponding to amino acid
position 240 that plays an important role in the resistance
pattern of CTX-Ms [32], was chosen for further discrimination of
the variants within the groups.
Amplification and specificity of qRT products
45 cycles were run to ensure that all reactions reached
saturation, and sufficient PCR product concentrations were
obtained for the following pyrosequencing reaction (see
Figures S2 and S3). Melting temperatures (Tm) of the CTX-M
products were determined, indicating similar values within the
groups (for details Table 2 and 3). Since similar melting
temperatures were also obtained for β-lactamases of the SHV-,
TEM- and OXA-families that were used as unspecific controls,
a melting curve analysis was unable to distinguish between
CTX-M and non CTX-M-types. Compared to the SHV-, TEM-,
OXY- and OXA-types, the ct values (cycle number at threshold)
for CTX-M-products were lower and the PCR-products of non-
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CTX-M variants crossed the threshold later, indicating
unspecific PCR-products. However, since ct values strongly
depend on template concentration, they are not sufficient for
discrimination between specific and non-specific targets.
Therefore, the specificity of the PCR-products was further
analyzed using agarose gel electrophoresis. Using the
degenerated primer sets mentioned above, only the CTX-M-
variants were successfully transcribed to cDNA and amplified
to specific products of 268 bp and 447 bp (Figure 2). The band
patterns of obtained amplicons for TEM-3, SHV-5, and OXA-10
contained many weak signals, indicating that these
degenerated primers annealed only non-specifically under the
given RT and qRT conditions.
Quality of the pyrograms
For sufficient interpretability, the required signal peaks have
to be twenty fold higher than the background signals. In
general, signal-to-noise ratio of the pyrograms obtained for the
region 1 (nucleic acid region +227 to +246) were of higher
quality, and the individual peaks could be clearly discriminated
for all CTX-M-types, independently of the phylogenetic group.
Pyrograms of region 2 (nucleic acid region +720 to +746) were
of minor quality compared to region 1, but were still evaluable.
The program signals of all nucleotide positions (NPs) allowed
satisfying discrimination between groups 1, 2, and 9. Groups 8
and 25 showed well evaluable peaks for NP 1 - NP 3. The non-
CTX-M β-lactamases (SHV, TEM, OXA) yielded very weak and
non-evaluable peaks.
Figure 1.  Alignment of representatives of the CTX-M groups.  The IUPAC code was used to highlight the variable nucleotides
within the primer sequences and the sequence positions analyzed by pyrosequencing, for the last the code displays the nucleotide
variants within the group (for example K in group 1 = G or T). Positions of PCR and sequencing primers (for details see Material and
Methods) are framed and the sense and antisense directions are indicated with arrows. The degenerated nucleotides within the
primer annealing positions are highlighted in grey.
doi: 10.1371/journal.pone.0080079.g001
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The pyrograms of region 1 of the mixed samples containing
various β-lactamases all exhibited good peak quality and
quantity and could be clearly discriminated.
CTX-M group differentiation based on region 1
In general, protocols for pyrosequencing are usually
designed for determination of only one or few substitutions
within a short sequence. However, in many CTX-M variants,
substitutions are distributed over the entire gene. For the
chosen discriminating region, ranging from +227 to +246
(Figure 1), we developed an optimized sequential application of
nucleotides including an unspecific adenine at nucleotide
position (NP) 4 that allowed a clear resolution of this position
bearing a high GC-content (for details see Figure 3). The
sequencing primer seqCTX-M211 was also designed as a
degenerated oligonucleotide. The read outs were evaluated by
the PyroMark Assay Design 2.0. Ink software. The probabilities
of the incorporated nucleotides at the positions of interest are
displayed as percentages (see Table 2). Specific distribution
patterns could be allocated to the individual groups: Cytosine at
NP 3 and NP 6 with an evidence of >90 % was unique for
Table 2. Analysis of region 1.
 RNA isolation qRT parameters NP 1 NP 2 NP 3 NP 4 NP 5 NP 6
Enzyme CRNA RIN Ct Tm A G G T (A) C G C T A G C G
CTX-M-1 23.7 8.9 19.57 89.25 100 0 100 0 10 90* 0 3 97* 8 92 100* 0
CTX-M-3 20.1 8 20.93 89.75 100 0 99 1 11 89* 0 68 32 9 91 96* 4
CTX-M-15 230 n.d. 17.4 89.9 100 0 99 1 13 97* 0 73 27 13 87 96* 4
CTX-M-2 61.2 8.1 22.44 91,00 24 76* 94 6 12 19 69 78 22 11 89 28 72
CTX-M-9 34.8 8.3 25.7 91.6 100 0 37 63* 10 30 60 63 37 20 80 36 64
CTX-M-14 48.4 9.3 22.54 91.5 100 0 59 41* 4 58 38 57 43 4 96 56 44
CTX-M-27 49.3 9 21.87 91.4 100 0 60 40* 3 60 36 52 48 4 96 63 37
CTX-M-8 26,0 8 25.83 91.6 0 100* 100 0 2 0 98* 89 11 89 11 0 100*
CTX-M-25 43.9 8 29.02 90.25 100 0 100 0 4 0 96* 90 10 94 6 1 99*
SHV-4 80 n.d. 35.41 92.85 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
TEM-2 45.1 n.d. 31.35 89.15 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
OXA-10 44.1 n.d. 32.01 92.6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d. = not detectable
* Nucleotide evidences discriminative for the corresponding nucleotide position
Parameters (concentration and RIN quality control) of the total RNA isolation, real-time PCR (ct value and melting temperature Tm) and substitutional analysis of the
nucleotide positions (NP) 1 to 6 of the pyrograms given as percent (%) of evidence.
doi: 10.1371/journal.pone.0080079.t002
Table 3. Analysis of region 2.
 qRT parameters NP 1 NP 2 NP 3 NP 4 NP 5 NP 6 NP 7
Enzyme Ct Tm G T A C T A G C T C T C T C T
CTX-M-1 16.82 94.0 87 13 6 11 83* 91* 9 96 4 14 86* 87 13 67 33
CTX-M-3 18.12 94.3 86 14 7 13 80* 92* 8 94 6 17 83* 85 15 65 35
CTX-M-15 17.14 94.5 96 4 3 8 89* 5 95* 98 2 10 90* 89 11 72 28
CTX-M-2 14.16 94.0 88 12 73* 14 13 94 6 16 84 10 90 83 17 64 36
CTX-M-9 22.71 95.8 90 10 6 59 35 95* 5 100* 0 62 38 90 10 68 32
CTX-M-14 19.69 96.0 89 11 5 46 49 94* 6 99* 1 49 51 91 3 68 32
CTX-M-27 19.12 96.0 93 7 4 45 51 55 45* 100* 0 46 54 90 10 72 28
CTX-M-8 30.14 92.5 53 47 18 36 46 91 9 60 40 45 55 39 61 47 53
CTX-M-25 22.44 93.5 96 4 0 86* 14 0 100 100 0 92 8 86 14 80 20
SHV-4 21.44 91.5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
TEM-2 30.78 87.6 (84.9)# n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
OXA-10 25.89 92.7 (89.7)# n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
* Nucleotide evidences discriminative for the corresponding nucleotide position
# Melting peak of a second PCR-product
Parameters of the real-time PCR (ct value and melting temperature Tm), and substitutional analysis of the nucleotide positions (NP) 1 to 7 of the pyrograms given as percent
(%) of evidence.
doi: 10.1371/journal.pone.0080079.t003
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group 1 members. Thymine at NP 4 differentiates the clinically
relevant CTX-M-1 and -32 and further variants (114, 116, 23,
52, 53, 55, 57, 60, 61, 69, and 79) from the other
representatives of group 1. Groups 8 and 25 showed unique
distributions for guanine at NP 3 and NP 6, simultaneously
differing at NP 1 with guanine for group 8 (100 %) and adenine
for group 25 (100 %). Variants of group 9 could be identified by
the thymine at NP 2 since group 1, 2, 8, and 25 exhibited
strong preferences to guanine (>94 %). Group 2 could be
distinguished from other groups by the presence of guanine at
NP 1 and NP 5, even when the evidence was only 76 % or 89
%, respectively. Guanine at NP 5 separated group 2 from
group 8 (adenine).
The non-CTX-M β-lactamases (SHV, TEM, OXA and NDM)
were not detected by the sequencing reaction even though
unspecific PCR products were generated in the qRT.
Differentiation of CTX-M variants based on region 2
By sequencing a second short region ranking from +720 to
+746, a more detailed discrimination of the variants of group 1,
9, and 25 could be obtained (Table 3). This position was
already described as discriminative for some subgroups by
Naas et al. [33]. Guanine at NP 3 (+726) corresponds to
Asp240Gly that confers increased ceftazidime resistance [34].
The sequences of group 1 showed the highest variance
within region 2, CTX-M-34 has a guanine at NP 1 and a
thymine at NP 4. Thymine at NP 4 was also present in CTX-
M-10, -37 and -53. Guanine at NP 3 was present within group 1
in many variants, of which some are highly clinically relevant.
Within group 9, guanines were found in CTX-M-16, 93, 121,
105, 98, 102, and -27, within group 2 in CTX-M-131 and -43,
and within group 25 in CTX-M-25, 94, 100, and -41. In
summary, presence of guanine at this position allowed
discrimination of the ceftazidime resistant CTX-M-phenotype.
Adenine at NP 2 (73 %) and thymine at NP 4 (84 %) allowed
a clear assignment to group 2. Thymine at NP 2 was unique for
group 1, whereas cytosine at NP 2 allocated variants to group
25 and group 9. In summary, region 2 yielded additional
information according the group allocation for 1, 2, 9 and 25.
Discriminative accuracy by coexistence of CTX-M with
other β-lactamases
To test the performance of the amplification-sequencing
method under “real life” conditions, we analyzed the efficiency
to discriminate the CTX-M-15 gene within various clinical
isolates, which also contained up to 6 other β-lactamase genes
of non-CTX-M type. Our results clearly showed that the
distribution of the incorporated nucleotides at all NPs was
similar to that of the control strain solely harboring CTX-M-15,
indicating that the presence of non-CTX-M lactamases does
not disturb the efficiency of the degenerated primers (Table 4).
Moreover, the primer sets produced only specific amplicons
when CTX-M genes were present simultaneously with non-
CTX-M genes (Figure 4). (Contrary, when no CTX-M gene was
Figure 2.  PCR products of various β-lactamases.  The qRT samples were analyzed on a 1.5 % agarose gel after 45 cycles
PCR. (A) PCR-products of NP- region 1; Lines: 1, 16= Low-range molecular ladder (Thermo Scientific), 2 = CTX-M-15, 3 = CTX-
M-1, 4 = CTX-M-2, 5 = CTX-M-3, 6 = CTX-M-9, 7 = CTX-M-14, 8 = CTX-M-27, 9 = SHV-4, 10 = TEM-1, 11 = OXA-10, 12 = TEM-1,
13 = NTC, 14 = CTX-M-8, 15 = CTX-M-25. (B) PCR-products of NP-region 2; 1, 16 and 19 = Low-range molecular ladder (Thermo
Scientific), 2 = 1 pg CTX-M-15, 3 = 10-1 pg CTX-M-15, 4 = 10-2 pg CTX-M-15, 5 = 10-3 pg CTX-M-15, 6 = CTX-M-1, 7 = CTX-M-2, 8
= CTX-M-3, 9 = CTX-M-9, 10 = CTX-M-14, 11 = CTX-M-27, 12 = OXA-1, 13 = OXA-10, 14 = TEM-2, 15 = SHV-4, 17 = CTX-M-8, 18
= CTX-M-25.
doi: 10.1371/journal.pone.0080079.g002
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present some unspecific PCR products could be determined
(Figure 2)). Due to the common co-existence of different β-
lactamases in clinical isolates, this robustness is crucial for
clinical applicability.
Discriminative performance of pyrosequencing
Analysis of pyrosequencing results for region 1 and region 2
of all variants revealed that this amplification-sequencing
approach was able to assign all tested CTX-M (n=120) variants
Table 4. Substitutional analysis of region 1 in the presence
of non-CTX-M β-lactamases.
 qRT parametersNP 1 NP 2 NP 3 NP 4 NP 5 NP 6
Enzyme Ct Tm A G G T A C G C T A G C G
CTX-M-15 24.63 89.75 98 2 100 0 3 97 0 89 11 4 96 88 12
RKI 01/10 18.90 89.65 98 2 100 0 3 97 0 89 11 4 96 91 9
RKI 02/10 17.82 89.65 99 1 100 0 2 98 0 90 10 4 96 95 5
RKI 93/07 20.50 89.65 99 1 100 0 2 98 0 90 10 3 97 89 11
RKI
364/12
17.74 89.65 97 3 100 0 5 95 0 85 15 4 96 78 22
Parameters of the real-time PCR (ct value and melting temperature Tm), and
substitutional analysis of the nucleotide positions (NP) 1 to 6 of the pyrograms
given as percent (%) of evidence. The various β-lactamases present in the strains
are listed in Table 1.
doi: 10.1371/journal.pone.0080079.t004
to the accurate type and group. Region 2 (NP 3 corresponding
to Asp240Gly), associated with increased ceftazidime
resistance, did not clearly differentiate between all CTX-M-
groups on its own. However, a combination of both the group-
discriminative nucleotide sequence downstream of +227
(region 1) and the second position related to ceftazidime
resistance increased the discriminative performance of the
method.
Naas et al. already described CTX-M characterization by
pyrosequencing [33] (in 57 isolates). They sequenced two
Figure 4.  PCR-products of mixed β-lactamase
samples.  The qRT samples were analyzed on a 1.5 %
agarose gel after 45 cycles PCR. (A) PCR-products of region 1;
Lines: 1, 8 = Low-range molecular ladder (Thermo Scientific), 2
= CTX-M-15, 3 = RKI 01/10, 4 = RKI 02/10, 5 = RKI 93/07, 6 =
RKI 364/12 .
doi: 10.1371/journal.pone.0080079.g004
Figure 3.  Representative pyrograms of CTX-M-1.  Sequence obtained by degenerated primer seqCTX-M211 (A) and seqCTX-M705 (B).
The sequentially applied nucleotides are given at the X-axis, alternative NPs are boxed and the bases are indicated on the top. The
Y-axis shows the relative signal intensity. The probabilities of the nucleotides were calculated by the PyroMark-evaluation software
in percent.
doi: 10.1371/journal.pone.0080079.g003
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regions, with one of them being identical to our region 2.
However, most of the discriminative NPs identified by Naas et
al. are located within the peripheral regions of the sequences,
which may impair correct and robust phylogenetic
discrimination. Possibly, a combination of all three conserved
regions may increase the phylogenetic accuracy.
How far this method is compatible with the commonly used
PCR-based multiplex techniques for differentiation of TEM,
SHV, or some OXA-variants needs to be evaluated (Figure 2).
Conclusions
The developed diagnostic approach focused on the specific
molecular determination of CTX-M β-lactamases and a
simultaneous discrimination of the sub-groups of this β-
lactamase type, to overcome the traditional time consuming
phenotypic resistance testing. In order to predict the resistance
phenotype more accurately, our focus of interest is mRNA
reflecting the expressed genes. We chose this approach since
clinical studies have demonstrated that the resistance
phenotype, but not the sole detection of a resistance gene, was
associated with an impaired clinical outcome, e.g. in Klebsiella
pneumoniae blood stream infections [35]. Moreover, since
usually many transcriptional copies of one gene can be
expected in one cell; focusing on mRNA could increase the
chance to determine even low cfu/ mL directly from blood
samples. However, further work on the usage of EDTA-blood
as direct material could be considered to improve the yield of
mRNA.
Due to the relative high variability of the CTX-M genes,
degenerated primers for RT, and qRT, as well as for
pyrosequencing, were used and the suitability and
discriminatory performance of two conserved positions within
the CTX-M genes were analyzed. The reaction-flow contained
a reverse transcription, followed by PCR and pyrosequencing,
using one protocol for all isolates and positions respectively.
Using this approach no information regarding the expected
CTX-M variant is needed, since all sequences are covered by
these degenerated primers.
This work demonstrates the potential of PCR-based
verification procedures and how they can be coupled to
pyrosequencing to discriminate a wide range of various
resistance genes. Our results suggest that the combination of
amplification and pyrosequencing can resolve the challenge of
continuously emerging new CTX-M variants and the quickly
changing local CTX-M epidemiology. In the context of the
ongoing fast global spread of emerging novel variants of β-
lactamases that are highly exchangeable, even between non-
related Gram-negative species, discrimination of pathogens in
clinical specimen alone is of minor use and will have to be
replaced by direct determination of expressed resistance genes
to select the best fitting antibiotic therapy [7,36]. Furthermore,
this PCR-based method, coupled to real-time sequencing, can
be a fast tool for outbreak analysis, tracing the clonal spread of
the resistance genes in hospitals.
Supporting Information
Figure S1.  Phylogenetic tree of 120 CTX-M variants.
Groups are indicated besides the respective variants.
(TIF)
Figure S2.  Sensorgrams of the qRT. A) Sensorgram of the
qRT run of 45 cycles; the ct-values were determined at a
threshold of 0.45. B) Melting curve analysis of the PCR-
products. Red colored lines indicated the CTX-M-15 that was
also used as a calibration standard. Colors are used as
indicated on the right site, NTC = negative control reaction
without template.
(TIF)
Figure S3.  Melting curve analysis of OXY-β-lactamase. No
PCR-products of OXY-β-lactamase (green and blue lines,
technical replicates) could be determined by using the
degenerated primer sets for reverse transcription and qPCR.
Linearized plasmidal encoded CTX-M-15 gene was used as a
positive control (red line). NTC = negative control reaction
without template (black line).
(TIF)
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